Symbols / ENSC Stock $0.36 -5.64% Ensysce Biosciences, Inc.

Healthcare • Biotechnology • United States • NCM
ENSC (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. D. Lynn Kirkpatrick Ph.D.
Exch · Country NCM · United States
Market Cap 3.35M
Enterprise Value -980.54K
Income -10.18M
Sales 5.07M
FCF (ttm) -4.42M
Book/sh 0.70
Cash/sh 0.47
Employees 8
Insider 10d —
IPO Mar 14, 2018
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -0.16
PEG —
P/S 0.66
P/B 0.51
P/C —
EV/EBITDA 0.10
EV/Sales -0.19
Quick Ratio 1.04
Current Ratio 1.59
Debt/Eq 10.63
LT Debt/Eq —
EPS (ttm) -3.98
EPS next Y -2.23
EPS Growth —
Revenue Growth 44.40%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-03-30
Earnings (prior) 2026-03-30
ROA -98.10%
ROE -3.25%
ROIC —
Gross Margin -104.81%
Oper. Margin -147.79%
Profit Margin -200.84%
Shs Outstand 9.28M
Shs Float 9.27M
Insider Own 0.11%
Instit Own 4.98%
Short Float 0.69%
Short Ratio 0.09
Short Interest 64.30K
52W High 3.23
vs 52W High -88.80%
52W Low 0.31
vs 52W Low 15.06%
Beta 1.14
Impl. Vol. —
Rel Volume 0.04
Avg Volume 6.16M
Volume 247.41K
Target (mean) $16.45
Tgt Median $16.45
Tgt Low $16.45
Tgt High $16.45
# Analysts 1
Recom None
Prev Close $0.38
Price $0.36
Change -5.64%
About

Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, develops prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, designed to release clinically effective drugs only when exposed to specific physiological conditions; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology. The company's lead product candidate is PF614, a TAAP oxycodone prodrug candidate for the treatment of severe or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat for overdose protection. It is also developing PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for attention deficit hyperactivity disorder; and PF9001 to treat Opioid use disorder.Ensysce Biosciences, Inc. was founded in 2003 and is based in La Jolla, California.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$16.45
Mean price target
2. Current target
$0.37
Latest analyst target
3. DCF / Fair value
$-8.57
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.37
Low
$16.45
High
$16.45
Mean
$16.45

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2023-09-25 main HC Wainwright & Co. Buy → Buy $7
2023-07-03 init HC Wainwright & Co. — → Buy $9
News
RSS: Latest ENSC news
Insider Transactions

No recent insider transactions.

Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Operating Expense
10.24
+52.17%
6.73
-37.21%
10.72
-55.75%
24.22
Research And Development
10.38
+43.74%
7.22
-4.85%
7.59
-61.75%
19.84
Selling General And Administration
4.93
+4.45%
4.72
-11.95%
5.36
-22.41%
6.91
General And Administrative Expense
4.93
+4.45%
4.72
-11.95%
5.36
-22.41%
6.91
Other Gand A
4.93
+4.45%
4.72
-11.95%
5.36
-22.41%
6.91
Other Operating Expenses
-5.07
+2.75%
-5.21
-133.58%
-2.23
+11.61%
-2.52
Total Expenses
10.24
+52.17%
6.73
-37.21%
10.72
-55.75%
24.22
Operating Income
-10.24
-52.17%
-6.73
+37.21%
-10.72
+55.75%
-24.22
Total Operating Income As Reported
-10.24
-52.17%
-6.73
+37.21%
-10.72
+55.75%
-24.22
EBITDA
-10.15
-51.58%
-6.70
+34.81%
-10.27
+57.37%
-24.10
Normalized EBITDA
-10.15
-51.58%
-6.70
+34.81%
-10.27
+57.37%
-24.10
Reconciled Depreciation
0.01
0.00
—
0.00
EBIT
-10.16
-51.68%
-6.70
+34.81%
-10.27
+57.37%
-24.10
Total Unusual Items
—
—
0.43
-92.52%
5.76
Total Unusual Items Excluding Goodwill
—
—
0.43
-92.52%
5.76
Special Income Charges
—
—
0.15
-91.83%
1.79
Other Special Charges
—
—
-0.15
+91.83%
-1.79
Net Income
-10.18
-27.40%
-7.99
+24.74%
-10.61
+56.09%
-24.17
Pretax Income
-10.18
-27.41%
-7.99
+24.84%
-10.63
+56.10%
-24.21
Net Non Operating Interest Income Expense
-0.02
+98.55%
-1.29
-264.59%
-0.35
+92.90%
-4.98
Interest Expense Non Operating
0.02
-98.55%
1.29
+264.59%
0.35
+223.16%
0.11
Net Interest Income
-0.02
+98.55%
-1.29
-264.59%
-0.35
+92.90%
-4.98
Interest Expense
0.02
-98.55%
1.29
+264.59%
0.35
+223.16%
0.11
Other Income Expense
0.08
+148.82%
0.03
-92.47%
0.45
-91.08%
5.00
Other Non Operating Income Expenses
0.08
+148.82%
0.03
-92.47%
0.45
-91.08%
5.00
Gain On Sale Of Security
—
—
0.28
-95.07%
5.76
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-10.18
-27.41%
-7.99
+24.84%
-10.63
+56.10%
-24.21
Net Income From Continuing Operation Net Minority Interest
-10.18
-27.40%
-7.99
+24.74%
-10.61
+56.09%
-24.17
Net Income From Continuing And Discontinued Operation
-10.18
-27.40%
-7.99
+24.74%
-10.61
+56.09%
-24.17
Net Income Continuous Operations
-10.18
-27.41%
-7.99
+24.84%
-10.63
+56.10%
-24.21
Minority Interests
0.00
+558.11%
0.00
-99.44%
0.01
-62.70%
0.04
Normalized Income
-10.18
-27.40%
-7.99
+24.74%
-10.61
+56.09%
-24.17
Net Income Common Stockholders
-10.18
-27.40%
-7.99
+24.83%
-10.63
+57.64%
-25.09
Otherunder Preferred Stock Dividend
0.00
-100.00%
0.00
-97.76%
0.01
-98.58%
0.91
Diluted EPS
-3.98
+65.24%
-11.45
+83.74%
-70.40
+96.63%
-2,091.60
Basic EPS
-3.98
+65.24%
-11.45
+83.74%
-70.40
+96.63%
-2,091.60
Basic Average Shares
2.56
+88.58%
1.36
+798.24%
0.15
+323.59%
0.04
Diluted Average Shares
2.56
+88.58%
1.36
+798.24%
0.15
+323.59%
0.04
Diluted NI Availto Com Stockholders
-10.18
-27.40%
-7.99
+24.83%
-10.63
+57.64%
-25.09
Total Other Finance Cost
—
—
—
4.88
Line Item Trend 2024-12-31 2023-12-31
Total Assets
5.60
+106.69%
2.71
Current Assets
5.34
+133.51%
2.29
Cash Cash Equivalents And Short Term Investments
3.50
+211.68%
1.12
Cash And Cash Equivalents
3.50
+211.68%
1.12
Receivables
0.12
+27.22%
0.10
Other Receivables
0.12
+27.22%
0.10
Prepaid Assets
1.70
+62.00%
1.05
Other Current Assets
0.02
+0.00%
0.02
Total Non Current Assets
0.25
-39.76%
0.42
Net PPE
0.00
0.00
Other Non Current Assets
0.25
-39.76%
0.42
Total Liabilities Net Minority Interest
2.22
-34.00%
3.36
Current Liabilities
2.21
-33.78%
3.33
Payables And Accrued Expenses
1.91
-23.11%
2.48
Payables
1.36
-29.90%
1.94
Accounts Payable
1.36
-29.90%
1.94
Current Accrued Expenses
0.55
+1.14%
0.54
Pensionand Other Post Retirement Benefit Plans Current
—
—
Current Debt And Capital Lease Obligation
0.30
-64.71%
0.85
Current Debt
0.30
-64.71%
0.85
Other Current Borrowings
0.30
-64.71%
0.85
Current Capital Lease Obligation
—
0.00
Current Deferred Liabilities
—
—
Current Deferred Revenue
—
—
Total Non Current Liabilities Net Minority Interest
0.01
-61.74%
0.03
Long Term Debt And Capital Lease Obligation
—
—
Long Term Debt
—
—
Other Non Current Liabilities
—
—
Stockholders Equity
3.71
+1248.62%
-0.32
Common Stock Equity
3.71
+1248.62%
-0.32
Capital Stock
0.00
+547.62%
0.00
Common Stock
0.00
+547.62%
0.00
Preferred Stock
0.00
0.00
Share Issued
1.36
+546.40%
0.21
Ordinary Shares Number
1.36
+546.41%
0.21
Treasury Shares Number
0.00
+20.00%
0.00
Additional Paid In Capital
133.25
+9.91%
121.23
Retained Earnings
-129.54
-6.57%
-121.56
Minority Interest
-0.33
-0.02%
-0.33
Total Equity Gross Minority Interest
3.38
+618.98%
-0.65
Total Capitalization
3.71
+1248.62%
-0.32
Working Capital
3.14
+400.50%
-1.04
Invested Capital
4.01
+654.00%
0.53
Total Debt
0.30
-64.71%
0.85
Net Debt
—
—
Capital Lease Obligations
—
0.00
Net Tangible Assets
3.71
+1248.62%
-0.32
Tangible Book Value
3.71
+1248.62%
-0.32
Derivative Product Liabilities
0.01
-61.74%
0.03
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-7.81
-4.05%
-7.50
+30.40%
-10.78
+39.73%
-17.89
Cash Flow From Continuing Operating Activities
-7.81
-4.05%
-7.50
+30.40%
-10.78
+39.73%
-17.89
Net Income From Continuing Operations
-10.18
-27.41%
-7.99
+24.84%
-10.63
+56.10%
-24.21
Depreciation Amortization Depletion
0.01
0.00
—
0.00
Depreciation
0.01
0.00
—
0.00
Depreciation And Amortization
0.01
0.00
—
0.00
Other Non Cash Items
0.68
-45.12%
1.24
+260.11%
0.34
-95.84%
8.29
Stock Based Compensation
0.18
+59.94%
0.11
-87.41%
0.88
-17.98%
1.07
Operating Gains Losses
-0.01
+38.03%
-0.02
+94.26%
-0.28
+95.78%
-6.74
Gain Loss On Investment Securities
-0.01
+38.03%
-0.02
+94.26%
-0.28
+95.78%
-6.73
Unrealized Gain Loss On Investment Securities
—
0.00
+100.00%
-0.15
+91.83%
-1.79
Change In Working Capital
1.52
+278.01%
-0.85
+10.12%
-0.95
-117.28%
5.48
Change In Receivables
-0.30
-1015.58%
-0.03
-114.81%
0.18
+8.71%
0.16
Change In Prepaid Assets
-0.44
-74.06%
-0.25
-118.10%
1.39
-15.77%
1.65
Change In Payables And Accrued Expense
2.25
+492.87%
-0.57
+77.26%
-2.52
-168.73%
3.66
Change In Accrued Expense
0.43
+6909.26%
0.01
+100.48%
-1.28
-225.72%
1.02
Change In Payable
1.82
+413.62%
-0.58
+53.10%
-1.23
-146.71%
2.64
Change In Account Payable
1.82
+413.62%
-0.58
+53.10%
-1.23
-146.71%
2.64
Investing Cash Flow
-0.12
0.00
0.00
-100.00%
0.00
Cash Flow From Continuing Investing Activities
-0.12
0.00
0.00
-100.00%
0.00
Net PPE Purchase And Sale
-0.12
0.00
—
—
Purchase Of PPE
-0.12
0.00
—
—
Capital Expenditure
-0.12
—
—
—
Net Other Investing Changes
—
—
—
0.00
Financing Cash Flow
8.74
-11.57%
9.88
+12.85%
8.76
-0.11%
8.77
Cash Flow From Continuing Financing Activities
8.74
-11.57%
9.88
+12.85%
8.76
-0.11%
8.77
Net Issuance Payments Of Debt
0.00
+100.00%
-0.49
-180.14%
0.61
-90.12%
6.13
Issuance Of Debt
—
0.00
-100.00%
1.61
-78.69%
7.53
Repayment Of Debt
0.00
+100.00%
-0.49
+51.49%
-1.00
+28.98%
-1.41
Long Term Debt Issuance
—
0.00
-100.00%
1.61
-78.69%
7.53
Long Term Debt Payments
0.00
+100.00%
-0.49
+51.49%
-1.00
+28.98%
-1.41
Net Long Term Debt Issuance
0.00
+100.00%
-0.49
-180.14%
0.61
-90.12%
6.13
Net Common Stock Issuance
1.10
-34.13%
1.67
-81.55%
9.05
+139.21%
3.78
Proceeds From Stock Option Exercised
4.77
-54.71%
10.54
0.00
0.00
Net Other Financing Charges
-1.11
+39.76%
-1.84
-104.62%
-0.90
+21.29%
-1.14
Changes In Cash
0.81
-66.02%
2.38
+217.51%
-2.02
+77.80%
-9.12
Beginning Cash Position
3.50
+211.68%
1.12
-64.30%
3.15
-74.34%
12.26
End Cash Position
4.31
+23.08%
3.50
+211.68%
1.12
-64.30%
3.15
Free Cash Flow
-7.93
-5.69%
-7.50
+30.40%
-10.78
+39.73%
-17.89
Income Tax Paid Supplemental Data
0.00
-21.88%
0.00
+0.00%
0.00
+100.00%
0.00
Common Stock Issuance
1.10
-34.13%
1.67
-81.55%
9.05
+139.21%
3.78
Issuance Of Capital Stock
5.08
+203.89%
1.67
-81.55%
9.05
+139.21%
3.78
Net Preferred Stock Issuance
3.98
0.00
—
—
Preferred Stock Issuance
3.98
0.00
—
—
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category